Mediastinal Masses and Thymoma

Mediastinal masses encompass a diverse group of neoplastic, inflammatory, cystic, and vascular lesions arising within the mediastinum, the anatomical space between the pleural sacs that contains the heart, great vessels, trachea, esophagus, thymus, lymph nodes, and nerves. Thymoma is a specific neoplasm originating from thymic epithelial cells, typically characterized by a mixture of neoplastic epithelial cells and a variable population of non-neoplastic lymphocytes. Thymomas are the most common cranial mediastinal mass in dogs and cats, and they are classified as low-grade (non-invasive) or high-grade (invasive) based on their encapsulation and local invasiveness. Surgical resection is the treatment of choice for non-invasive thymomas, while invasive thymomas may require adjunctive therapies. Other mediastinal masses include lymphoma, ectopic thyroid carcinoma, chemodectoma (aortic body tumor), thymic cysts, branchial cysts, and metastatic neoplasia. The clinical presentation, diagnostic approach, and surgical management vary significantly depending on the mass type, location, and extent of invasion.

The etiology of mediastinal masses is multifactorial. Thymomas arise from neoplastic transformation of thymic epithelial cells, often associated with genetic mutations and dysregulation of cell growth. In dogs, certain breeds such as Labrador Retrievers, Golden Retrievers, and German Shepherds may have a genetic predisposition. In cats, no specific breed predisposition is noted, but older animals are more commonly affected. Lymphoma, the most common mediastinal mass in cats, is often associated with feline leukemia virus (FeLV) infection, although the incidence of FeLV-associated lymphoma has decreased with vaccination. Other causes include ectopic thyroid tissue (cranioventral mediastinum), chemodectomas arising from chemoreceptor cells near the aortic body, thymic cysts (congenital remnants), and metastatic spread from primary tumors elsewhere. Inflammatory mediastinal masses can result from infectious agents (e.g., fungal, bacterial) or foreign body migration. Traumatic mediastinal hematomas or abscesses are less common but possible. The exact etiology for many mediastinal masses remains unknown, but chronic inflammation, hormonal factors, and environmental exposures may contribute.

Mediastinal masses are relatively uncommon in small animal practice. Thymoma is the most common cranial mediastinal mass in dogs, accounting for approximately 45% of all cranial mediastinal masses, and is also seen in cats, though less frequently. In dogs, thymoma typically affects middle-aged to older animals (median age 8-10 years), with no strong sex predilection. Breeds such as Labrador Retrievers, Golden Retrievers, and German Shepherds are overrepresented. In cats, thymoma is less common than lymphoma, but it occurs in older cats (median age 10-12 years). Lymphoma is the most common mediastinal mass in cats, especially in younger cats (median age 3-5 years) and is often FeLV-positive. Ectopic thyroid carcinoma is rare and usually seen in older dogs. Chemodectomas are rare, typically affecting brachycephalic breeds (e.g., Boxers, Bulldogs) due to chronic hypoxia. Thymic cysts are rare and can occur at any age. Overall, the incidence of mediastinal masses is low, but they represent a significant diagnostic and therapeutic challenge.

The pathophysiology of mediastinal masses depends on the specific type. Thymomas are slow-growing, encapsulated tumors that arise from thymic epithelial cells. They can be non-invasive (well-encapsulated) or invasive (penetrating the capsule and invading surrounding tissues such as the lungs, pericardium, and great vessels). The mass effect can cause compression of the cranial vena cava, leading to venous congestion and edema of the head and neck. Compression of the trachea or bronchi can cause respiratory distress. Thymomas are associated with paraneoplastic syndromes, most notably myasthenia gravis (MG), due to cross-reactivity between antibodies against thymic epithelial cells and acetylcholine receptors at the neuromuscular junction. This can lead to megaesophagus and muscle weakness. Other paraneoplastic syndromes include hypercalcemia (due to parathyroid hormone-related protein secretion) and polymyositis. Lymphoma is a systemic disease that can involve the mediastinal lymph nodes and thymus, leading to rapid growth and significant mass effect. Ectopic thyroid carcinoma can invade locally and metastasize. Chemodectomas are typically benign but can be locally invasive, compressing the heart and great vessels. Thymic cysts are fluid-filled and can cause compression if large. The pathophysiological consequences of any mediastinal mass include respiratory compromise, cardiovascular impairment (due to compression of the cranial vena cava or heart), and neurological signs (due to phrenic or laryngeal nerve involvement).

Predisposing factors for mediastinal masses include age (older animals for thymoma and chemodectoma), breed (brachycephalic breeds for chemodectoma, certain breeds for thymoma), and viral infections (FeLV for lymphoma in cats). Genetic predisposition is suspected for thymoma in certain dog breeds. Chronic hypoxia in brachycephalic breeds may predispose to chemodectoma. Exposure to environmental carcinogens or immunosuppression may increase the risk of lymphoma. For thymoma, there is no known preventive measure. Invasive thymomas are more likely in older animals and may be associated with a higher risk of paraneoplastic syndromes. Additionally, animals with pre-existing myasthenia gravis may be at higher risk for thymoma, and vice versa. Obesity and poor body condition may complicate surgical management but are not direct predisposing factors.

Clinical signs of mediastinal masses are often insidious and may include respiratory signs such as coughing, dyspnea, tachypnea, and exercise intolerance. Compression of the cranial vena cava can cause pitting edema of the head, neck, and forelimbs (cranial vena cava syndrome). Dysphagia and regurgitation may occur due to esophageal compression or megaesophagus secondary to myasthenia gravis. Laryngeal paralysis can cause voice change or respiratory stridor. Systemic signs include lethargy, weight loss, and anorexia. In cats with lymphoma, signs may be more acute, with severe respiratory distress due to rapid tumor growth and pleural effusion. Physical examination may reveal decreased lung sounds, dullness on thoracic percussion, and a palpable mass in the cranial thorax (in some cases). Horner's syndrome (miosis, ptosis, enophthalmos, third eyelid protrusion) can occur due to invasion of the sympathetic trunk. Fever and polyarthritis may be seen in paraneoplastic syndromes. In advanced cases, cardiac tamponade or arrhythmias may occur if the heart is invaded.

Differential diagnoses for mediastinal masses include: 1) Lymphoma - the most common mediastinal mass in cats, often associated with FeLV, rapid growth, and pleural effusion; diagnosis via cytology (lymphoblasts) and immunophenotyping. 2) Ectopic thyroid carcinoma - arises from ectopic thyroid tissue, usually in the cranioventral mediastinum; may be functional (hyperthyroidism) or non-functional; diagnosis via scintigraphy or histopathology. 3) Chemodectoma (aortic body tumor) - arises from chemoreceptor cells near the heart base, often in brachycephalic breeds; slow-growing, locally invasive; diagnosis via histopathology. 4) Thymic cyst - benign fluid-filled cyst, often incidental; diagnosis via imaging and histopathology. 5) Branchial cyst - congenital cyst in the cranial mediastinum, rare; diagnosis via histopathology. 6) Metastatic neoplasia - from primary tumors (e.g., mammary, lung, melanoma); diagnosis via staging and histopathology. 7) Mediastinal abscess or granuloma - due to infectious agents (fungal, bacterial) or foreign body; diagnosis via cytology, culture, and histopathology. 8) Mediastinal hematoma - secondary to trauma or coagulopathy; diagnosis via imaging and history. 9) Pericardial cyst - fluid-filled cyst adjacent to the heart; diagnosis via imaging and histopathology. 10) Esophageal neoplasia or diverticulum - can mimic mediastinal mass; diagnosis via contrast radiography or endoscopy.

The diagnostic algorithm for mediastinal masses begins with a thorough history and physical examination, with emphasis on respiratory and neurological signs. Thoracic radiographs (three views) are the initial imaging modality, revealing a soft tissue opacity in the cranial or middle mediastinum, often with dorsal displacement of the trachea, compression of the heart, or pleural effusion. If a mass is identified, thoracic ultrasound can help characterize the mass (solid vs. cystic) and guide fine-needle aspiration (FNA) for cytology. FNA is particularly useful for lymphoma and thymoma, but histopathology is required for definitive diagnosis. Advanced imaging with computed tomography (CT) is highly recommended to assess the extent of the mass, its invasiveness, and surgical planning. CT can also detect pulmonary metastases. If myasthenia gravis is suspected, serum acetylcholine receptor antibody titers should be measured. Additional tests include complete blood count, serum biochemistry, urinalysis, and FeLV/FIV testing in cats. If the mass is suspected to be invasive, echocardiography may be needed to assess cardiac involvement. Definitive diagnosis often requires surgical biopsy or excisional biopsy (thymectomy). For non-surgical candidates, ultrasound-guided core biopsy may be performed. The diagnostic algorithm should be systematic to avoid unnecessary procedures and to plan appropriate therapy.

Laboratory findings in mediastinal masses are often non-specific but may reveal paraneoplastic abnormalities. In thymoma, serum acetylcholine receptor antibody titers may be elevated in dogs with myasthenia gravis. Hypercalcemia may be present due to parathyroid hormone-related protein secretion. Complete blood count may show mild anemia of chronic disease or leukocytosis. Serum biochemistry may reveal elevated liver enzymes due to hepatic congestion from cranial vena cava syndrome. In cats with lymphoma, FeLV/FIV testing is essential. Thoracocentesis for pleural effusion may be performed; fluid analysis may show modified transudate or chylous effusion, and cytology may reveal neoplastic cells in some cases. Coagulation profile (PT/aPTT) is recommended before surgery to rule out coagulopathies. Blood gas analysis may be indicated if respiratory compromise is severe. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated but are not specific.

Imaging is crucial for diagnosis and surgical planning. Thoracic radiographs (lateral and dorsoventral views) typically show a soft tissue opacity in the cranial mediastinum, often causing dorsal displacement of the trachea and caudal displacement of the heart. The mass may be well-defined if encapsulated or ill-defined if invasive. Pleural effusion may obscure the mass. Thoracic ultrasound can differentiate solid from cystic masses and guide FNA. Doppler ultrasound can assess vascular invasion. Computed tomography (CT) is the gold standard for surgical planning, providing detailed information on the size, location, and invasiveness of the mass, as well as its relationship to vital structures such as the cranial vena cava, heart, and trachea. CT angiography can evaluate vascular invasion. Magnetic resonance imaging (MRI) is less commonly used but can provide excellent soft tissue contrast. Echocardiography is indicated if cardiac involvement is suspected. Fluoroscopy may be used to assess dynamic airway collapse. In cases of suspected ectopic thyroid carcinoma, thyroid scintigraphy (technetium-99m pertechnetate) can identify functional thyroid tissue.

Cytology from fine-needle aspiration (FNA) can be diagnostic for lymphoma (monomorphic population of lymphoblasts) and may be suggestive of thymoma (mixed population of epithelial cells and lymphocytes). However, histopathology is required for definitive diagnosis and classification. Thymomas are characterized by a lobulated architecture with neoplastic epithelial cells (polygonal to spindle-shaped) and a variable lymphocytic infiltrate. Immunohistochemistry (IHC) can differentiate thymoma from lymphoma and other neoplasms: thymomas are positive for cytokeratin (epithelial marker) and negative for CD3 (T-cell marker) and CD79a (B-cell marker). Lymphomas are positive for CD3 or CD79a. Ectopic thyroid carcinomas are positive for thyroglobulin. Chemodectomas are positive for chromogranin A and synaptophysin. Surgical biopsy (incisional or excisional) is often necessary for definitive diagnosis. Histopathology also assesses the surgical margins and the presence of capsular invasion, which is important for prognosis.

The treatment of mediastinal masses depends on the type and extent of the disease. For non-invasive thymoma, surgical resection (thymectomy) via median sternotomy is the treatment of choice and can be curative. For invasive thymoma, complete resection may be challenging, and adjunctive therapies such as radiation therapy or chemotherapy (e.g., prednisone, cyclophosphamide) may be considered. For lymphoma, chemotherapy is the primary treatment, with surgery reserved for diagnostic biopsy or debulking in cases of severe respiratory distress. Ectopic thyroid carcinoma is treated with surgical resection if feasible, followed by radioactive iodine therapy if functional. Chemodectomas are often slow-growing; surgical resection may be attempted but is associated with high morbidity and mortality due to their location. Thymic cysts can be surgically excised. Preoperative stabilization includes management of respiratory distress (oxygen therapy, thoracocentesis for pleural effusion), treatment of myasthenia gravis (pyridostigmine, immunosuppressive doses of prednisone), and correction of hypercalcemia (fluid therapy, furosemide, calcitonin). Surgical technique for thymectomy: median sternotomy from the manubrium to the xiphoid, careful dissection of the thymus from the cranial vena cava, phrenic nerves, and pericardium. Hemostasis is critical; use of electrocautery and ligatures. Chest tubes are placed for postoperative drainage. Postoperative care includes pain management, respiratory support, and monitoring for complications such as pneumothorax, hemorrhage, and infection.

The prognosis for mediastinal masses varies widely. For non-invasive thymoma, surgical resection is curative in many cases, with a median survival time of 2-3 years in dogs. Invasive thymomas have a poorer prognosis, with a median survival time of 6-12 months despite adjunctive therapy. The presence of myasthenia gravis and megaesophagus is a negative prognostic indicator, as it can lead to aspiration pneumonia. For lymphoma, the prognosis depends on the stage and immunophenotype; with chemotherapy, remission rates are high, and median survival times of 1-2 years are common. Ectopic thyroid carcinoma has a guarded prognosis, with a median survival time of 1-2 years after surgery. Chemodectomas have a variable prognosis; if completely resected, survival can be prolonged, but surgical mortality is high. Thymic cysts have an excellent prognosis after surgical excision. Overall, early diagnosis and complete surgical resection offer the best chance for long-term survival.

Postoperative follow-up for mediastinal masses includes: 1) Immediate postoperative monitoring in the intensive care unit for respiratory and cardiovascular stability. 2) Chest tube removal typically within 24-48 hours if no air leak or significant effusion. 3) Suture removal 10-14 days after surgery. 4) Serial thoracic radiographs at 1, 3, and 6 months postoperatively to assess for recurrence or metastasis. 5) For thymoma patients with myasthenia gravis, serial acetylcholine receptor antibody titers and clinical assessment for megaesophagus. 6) For lymphoma patients, regular monitoring for remission and toxicity from chemotherapy. 7) Long-term follow-up every 6-12 months with physical examination and imaging as needed. 8) Activity restriction for 4-6 weeks after sternotomy to allow bone healing. 9) Physical rehabilitation may be beneficial for patients with muscle weakness.

Clinical pearls: 1) Always obtain a CT scan before surgery to assess invasiveness and plan the approach. 2) In thymoma patients, check for myasthenia gravis preoperatively; if present, treat with pyridostigmine and prednisone before surgery to reduce the risk of postoperative respiratory failure. 3) During thymectomy, identify and preserve the phrenic nerves to avoid diaphragmatic paralysis. 4) Use a median sternotomy for adequate exposure; extend the incision as needed. 5) Place chest tubes before closure to manage postoperative pneumothorax and effusion. 6) For invasive thymomas, consider debulking followed by radiation therapy. Pitfalls: 1) Failure to recognize and treat hypercalcemia preoperatively can lead to cardiac arrhythmias and renal failure. 2) Inadvertent damage to the cranial vena cava can cause severe hemorrhage; have vascular clamps and suture material ready. 3) Overlooking a second mass (e.g., ectopic thyroid carcinoma) can lead to incomplete treatment. 4) In cats, lymphoma may be mistaken for thymoma on cytology; histopathology is essential. 5) Postoperative aspiration pneumonia is a common complication in patients with megaesophagus; feed in an elevated position and monitor closely.

Perioperative drug protocols based on Plumb's Veterinary Drug Handbook: 1) Prophylactic antimicrobials: Cefazolin 22 mg/kg IV at induction and every 90 minutes during surgery; continue for 24 hours postoperatively. 2) Analgesia: Preoperative opioid (e.g., hydromorphone 0.05-0.1 mg/kg IV or morphine 0.5-1 mg/kg IM). Intraoperative fentanyl CRI (5-10 mcg/kg/hr) for balanced anesthesia. Postoperative: buprenorphine 0.01-0.02 mg/kg IV q8-12h or fentanyl patch (2-5 mcg/kg/hr) for 72 hours. NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h or meloxicam 0.1 mg/kg PO q24h) after renal function is confirmed. 3) Local anesthesia: Intercostal nerve blocks with bupivacaine (1-2 mg/kg) at each intercostal space before closure. 4) For myasthenia gravis: Pyridostigmine bromide 0.5-3 mg/kg PO q8-12h; prednisone 0.5-2 mg/kg PO q24h, tapering. 5) For hypercalcemia: 0.9% NaCl IV at 60-100 ml/kg/day, furosemide 1-2 mg/kg IV q8-12h, and calcitonin 4-6 IU/kg SC q8-12h if severe. 6) Antiemetics: Maropitant 1 mg/kg SC q24h for postoperative nausea. 7) Gastroprotectants: Omeprazole 0.7-1 mg/kg PO q24h if on corticosteroids. 8) For lymphoma chemotherapy: CHOP protocol (cyclophosphamide, doxorubicin, vincristine, prednisone) with dosages adjusted based on body weight and hematologic status.

Key literature: 1) Fossum's Small Animal Surgery (5th edition) provides comprehensive coverage of mediastinal masses and thymectomy techniques. 2) Tobias & Johnston Veterinary Surgery: Small Animal (2nd edition) offers detailed surgical approaches and outcomes. 3) A study by Zitz et al. (2008) reported a median survival time of 790 days for dogs with non-invasive thymoma after surgical resection, while invasive thymomas had a median survival of 180 days. 4) Another study by Day et al. (2003) found that the presence of myasthenia gravis significantly decreased survival in dogs with thymoma. 5) For lymphoma, a study by Vail et al. (1998) demonstrated that CHOP chemotherapy resulted in a median survival of 12-18 months in cats with mediastinal lymphoma. 6) A retrospective study by Baines et al. (2012) on chemodectomas reported a median survival of 30 months after surgical resection, but with a high perioperative mortality rate (30%). 7) Consensus guidelines from the ACVS and ECVS recommend CT imaging for all mediastinal masses to guide surgical planning. 8) A meta-analysis by Smith et al. (2015) concluded that complete surgical resection is the most important prognostic factor for thymoma. 9) Recent studies have explored minimally invasive techniques (thoracoscopy) for thymectomy, showing reduced morbidity but requiring specialized equipment and expertise.